McKesson (MCK) Earnings Date & Reports

Key Takeaways

• Adjusted EPS beat expectations: McKesson reported adjusted earnings per diluted share of $11.69 for Q4, surpassing the consensus estimate of approximately $11.56 and rising 16% year-over-year.
• Revenue fell short: Quarterly consolidated revenues of $96.3 billion grew 6% from the prior year but missed analyst forecasts of roughly $101.9 billion, pressured by lower branded pharmaceutical pricing.
• Full-year performance exceeded targets: Fiscal 2026 adjusted EPS of $39.11 marked an 18% increase, above the company's long-range growth targets, on full-year revenue of $403.4 billion, up 12%.
• Oncology & Multispecialty was the standout segment: Revenue surged 35% to $12.7 billion and adjusted operating profit jumped 53% to $385 million, fueled by provider expansion and acquisitions.
• Aggressive capital return announced: The board authorized a $5 billion increase to the share repurchase program, bringing total authorization to $7.7 billion, alongside a $2.25 billion accelerated share repurchase.

Earnings Context and Why It Matters

McKesson's fiscal 2026 fourth-quarter results, released on May 7, 2026, capped a transformative year for the healthcare distribution and services giant. The company, which posted full-year revenue of $403.4 billion, is navigating a deliberate strategic pivot toward higher-margin specialty areas — particularly oncology and biopharma services — while managing headwinds in traditional pharmaceutical distribution. This quarter also brought progress on the planned separation of the Medical-Surgical Solutions segment, including a minority investment by Apollo Global Management at a $13 billion enterprise value. For investors, these results offered a clear progress report on McKesson's ability to sustain above-target earnings growth while reshaping its portfolio for the long term.

Reported Results

For the fourth quarter ended March 31, 2026, McKesson posted consolidated revenues of $96.3 billion, a 6% increase from $90.8 billion in the same period a year ago. The top line was driven by growth in the Oncology & Multispecialty segment and by higher prescription volumes in North American Pharmaceutical, though these gains were partially offset by lower branded pharmaceutical pricing, which shaved roughly 3 percentage points off revenue growth.

On a GAAP (Generally Accepted Accounting Principles) basis, earnings per diluted share reached $13.71, compared to $10.01 in the prior-year quarter. The jump reflected several discrete items, including net gains of $480 million from the divestiture of McKesson's Norwegian retail and distribution businesses, non-cash adjustments related to the Core Ventures acquisition, and a LIFO (Last-In, First-Out) inventory credit. Adjusted earnings per diluted share — which excludes these and other one-time items — came in at $11.69, up 16% from $10.12 a year ago and comfortably above the consensus estimate of $11.56.

For the full fiscal year, McKesson delivered adjusted EPS of $39.11 on revenue of $403.4 billion, representing 18% and 12% growth, respectively. Cash flow from operations reached $6.2 billion, producing free cash flow of $5.4 billion.

Segment results revealed a widening performance gap. North American Pharmaceutical, the largest segment, posted $79.1 billion in quarterly revenue, up 3%, with adjusted operating profit rising 11% to $980 million. Prescription Technology Solutions grew revenue 12% to $1.5 billion, with operating profit up 13% to $322 million. Medical-Surgical Solutions was the weakest link, with revenue nearly flat at $2.9 billion and operating profit declining 5% to $271 million. By contrast, Oncology & Multispecialty delivered standout growth: revenue rose 35% to $12.7 billion and adjusted operating profit jumped 53% to $385 million, driven by provider solutions, specialty distribution, and contributions from acquisitions such as PRISM Vision Group and Core Ventures.

AI Screener

For investors seeking to identify opportunities across the healthcare distribution sector and beyond, Tickeron's AI Screener offers a powerful way to filter thousands of stocks and ETFs using AI-driven signals, technical patterns, fundamental metrics, and customizable criteria such as industry, market capitalization, and volatility. The screener helps traders and investors efficiently surface trade ideas, breakout candidates, and trending stocks — reducing the time spent on manual research. Explore the AI Screener to see how data-driven screening can complement your market analysis.

Market Reaction and Investor Sentiment

McKesson shares were down approximately 0.4% in after-hours trading following the May 7 release, reflecting a mixed reception. While the adjusted EPS beat validated the company's profit execution, the significant revenue miss — reported at $96.3 billion versus consensus expectations above $101 billion — raised questions about top-line momentum in the core distribution business. The stock had already declined roughly 9.7% year-to-date through the report date, underperforming the S&P 500, as investors weighed concerns around branded pharmaceutical pricing pressure and softer Medical-Surgical performance. Sentiment was supported, however, by the aggressive capital return announcements and the raised long-term EPS growth target, which signaled management's confidence in sustained profitability even amid uneven revenue trends.

Forward Outlook and Key Factors to Monitor

McKesson initiated fiscal 2027 adjusted EPS guidance of $43.80 to $44.60, representing 12% to 14% growth over fiscal 2026, and reaffirmed its long-term adjusted EPS growth target of 13% to 16%. This outlook assumes continued strength in Oncology & Multispecialty, steady demand in North American Pharmaceutical, and a gradual recovery in Medical-Surgical Solutions.

Several catalysts and risk factors merit attention in the coming quarters. The planned separation of Medical-Surgical Solutions — including Apollo's 13% minority stake at a $13 billion valuation — could unlock significant shareholder value and sharpen strategic focus, but execution risk remains. GLP-1 (glucagon-like peptide-1) drug distribution, which generated $53 billion in full-year revenue, remains a meaningful growth driver, though sequential volume moderation in Q4 warrants monitoring. Branded pharmaceutical pricing trends and manufacturer price actions will continue to influence reported revenue in the North American Pharmaceutical segment, even if operating profit impact remains limited.

Additionally, McKesson's acquisition strategy in oncology provider services and specialty distribution adds upside potential but introduces integration complexity. The company added more than 570 providers to The US Oncology Network during fiscal 2026, the largest net increase since 2010 — a sign of sustained investment in higher-margin care delivery. With robust free cash flow, a fortified buyback program, and a portfolio increasingly weighted toward specialty and oncology, McKesson enters fiscal 2027 with meaningful momentum but also exposure to evolving reimbursement, regulatory, and competitive dynamics across the healthcare landscape.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations